Eckert & Ziegler SE: Steady Growth Amid Challenges

Eckert & Ziegler SE, a prominent player in the health care sector, has demonstrated resilience and growth in the first quarter of 2025. Despite facing a challenging start to the year, the company has confirmed its annual forecast, projecting an 8% increase in revenue to approximately €320 million. This optimistic outlook comes despite a subdued start, influenced by a cyberattack in February.

In the first quarter, Eckert & Ziegler reported a revenue increase to €68.2 million from €67.6 million in the same period the previous year. The operational result before special effects rose by 8% to €16.2 million. These figures underscore the company’s ability to maintain growth momentum even in the face of external disruptions.

The company, headquartered in Berlin, specializes in manufacturing low-level radiation sources for treating various diseases, including cancer and heart conditions. Additionally, it calibrates gamma cameras and positron emission tomographs, and develops cancer drugs, with a global market presence.

Despite the cyberattack’s impact, Eckert & Ziegler’s stock experienced a decline, reflecting investor concerns over the initial market performance. However, the company’s commitment to its growth trajectory remains unwavering.

Eckert & Ziegler is listed on the Xetra stock exchange, with a market capitalization of €1.27 billion as of May 8, 2025. The company’s price-to-earnings ratio stands at 31.28, with a close price of €59.3 on the same date. The stock has seen fluctuations, with a 52-week high of €62.05 and a low of €36.8.

In summary, Eckert & Ziegler SE continues to navigate challenges with a focus on growth, maintaining a positive outlook for the year ahead. The company’s strategic initiatives and resilience in the face of adversity position it well within the health care equipment and supplies industry.